The National Health Insurance Administration (NHIA) convened the meeting of the Pharmaceutical Benefit and Reimbursement Scheme Joint Committee on December 17, 2020. The meeting has passed the proposal of some new drugs included under NHI coverage and extended coverage. These coverages are mainly related to new chemical entities treating melanoma, triple-negative breast cancer, prostate cancer, multiple sclerosis, and migraine, and of antifungal agents and new antibiotic drugs used to treat antibiotic-resistant bacteria. The main drugs included under NHI coverage in this meeting were as follows:

1. The dual targeted therapy drug dabrafenib/trametinib for the treatment of melanoma with BRAF V600 mutation is included under NHI coverage. It is estimated that about 30 to 60 patients will be benefited each year within 5 years.
2. The second oral PARP inhibitor talazoparib for the treatment of triple-negative breast cancer is included under NHI coverage. It is estimated that about 40 to 50 patients will be benefited each year within five years.
3. The new drug containing apalutamide for the treatment of "high risk non-metastatic castration-resistant prostate cancer (nmCRPC)" and "metastatic castration sensitive prostate cancer (mCSPC)" is expected to benefit about 400 to 800 patients each year within 5 years.
4. The new drug containing siponimod for the treatment of secondary progressive multiple sclerosis is expected to benefit about 40 to 50 patients each year within 5 years.
5. The new drug containing galcanezumab for preventing migraine in adults is expected to benefit about 400 to 900 patients each year within 5 years.